Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1161-1170 of 1,873) with videos related to

Pageof 188
Sort By:
JAMA Cardiology|April 5, 2018
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF TrialAlvin Chandra, Eldrin F Lewis, Brian L Claggett, et al.
American Heart Journal|December 6, 2011
Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fractionAkshay S Desai, Eldrin F Lewis, Rebecca Li, et al.
European Heart Journal|June 29, 2025
Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statementBettina Heidecker, Peter Libby, Vassilios S Vassiliou, et al.
Journal of the American Heart Association|January 21, 2015
Beat-to-beat spatiotemporal variability in the T vector is associated with sudden cardiac death in participants without left ventricular hypertrophy: the Atherosclerosis Risk in Communities (ARIC) StudyJonathan W Waks, Elsayed Z Soliman, Charles A Henrikson, et al.
JAMA Cardiology|March 17, 2019
Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO StudyMasatoshi Minamisawa, Brian Claggett, David Adams, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 4, 2017
Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT TrialM C Foster, D E Weiner, A G Bostom, et al.
JAMA|November 9, 2015
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized TrialMihai Gheorghiade, Stephen J Greene, Javed Butler, et al.
Journal of the American Heart Association|March 7, 2025
Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic CardiomyopathyBryton J Davis, Hailey Volk, Olives Nguyen, et al.
Journal of the American College of Cardiology|November 15, 2019
Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEFMuthiah Vaduganathan, Brian L Claggett, Akshay S Desai, et al.
Circulation|July 20, 2007
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programSatish Kenchaiah, Stuart J Pocock, Duolao Wang, et al.
Pageof 188

Showing results (1161-1170 of 1,873) with videos related to

Sort By:
Pageof 188
JAMA Cardiology|April 5, 2018
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF TrialAlvin Chandra, Eldrin F Lewis, Brian L Claggett, et al.
American Heart Journal|December 6, 2011
Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fractionAkshay S Desai, Eldrin F Lewis, Rebecca Li, et al.
European Heart Journal|June 29, 2025
Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statementBettina Heidecker, Peter Libby, Vassilios S Vassiliou, et al.
Journal of the American Heart Association|January 21, 2015
Beat-to-beat spatiotemporal variability in the T vector is associated with sudden cardiac death in participants without left ventricular hypertrophy: the Atherosclerosis Risk in Communities (ARIC) StudyJonathan W Waks, Elsayed Z Soliman, Charles A Henrikson, et al.
JAMA Cardiology|March 17, 2019
Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO StudyMasatoshi Minamisawa, Brian Claggett, David Adams, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 4, 2017
Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT TrialM C Foster, D E Weiner, A G Bostom, et al.
JAMA|November 9, 2015
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized TrialMihai Gheorghiade, Stephen J Greene, Javed Butler, et al.
Journal of the American Heart Association|March 7, 2025
Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic CardiomyopathyBryton J Davis, Hailey Volk, Olives Nguyen, et al.
Journal of the American College of Cardiology|November 15, 2019
Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEFMuthiah Vaduganathan, Brian L Claggett, Akshay S Desai, et al.
Circulation|July 20, 2007
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programSatish Kenchaiah, Stuart J Pocock, Duolao Wang, et al.
Pageof 188